A spin-off from Sanofi in 1993, Unither is a pharmaceutical contract manufacturing organization (“CDMO”) specializing in the production and development of complex sterile liquid products for medical purposes.

The company is the world leader in blow-fill-seal (BFS) technology, which uses sterile unit doses to eliminate the need for preservatives. Unither has eight production sites in France, the United States, China and Brazil, as well as a dedicated research and development center in Europe.

NiXEN has decided to participate in this LBO as a co-investor alongside Keensight Capital, which is increasing its stake in Unither in order to support the management team in the next stages of the company’s international development.